Samsung Biologics Expands Global Footprint

Samsung Biologics has opened its first U.S. CDO R&D Center in San Francisco, CA, bringing its contract development services closer to global clients. Aligned with the company’s mission to offer a seamless one-stop service, the new facility will utilize the same CDO research and development capabilities present at its headquarters in Incheon, South Korea. Samsung Biologics says its CDO business delivers cell line development to DS manufacturing in six months, and to DP manufacturing in seven months.

“We’re starting the CDO R&D Center today in San Francisco, and we plan to continue our expansion into Boston, Europe, and China moving forward. In 2020 and beyond, our next decade will be marked by global geographical expansion,” said Tae Han Kim, chief executive officer, Samsung Biologics. “Samsung Biologics will continue to provide biopharmaceutical development and manufacturing services with top-notch capabilities and capacity, so that biotech and pharmaceutical companies can focus on their expertise: the discovery, development, or marketing and sales of novel biologics for patients.” 

Since its launch, the Samsung Biologics’ CDO business has been growing at a fast rate, contracting nearly 60 projects within just two years and establishing its proprietary cell-line, S-CHOice, showing improved titers up to two-fold from the industry average and maintaining over 90% cell viability.